Ondansetron Stada (Ondansetron Hydrochloride Dihydrate)

Ondansetron Stada belongs to the 5‑HT3 antagonist class and is used to control nausea and vomiting in several clinical situations.

• Chemotherapy‑induced nausea and vomiting: reduces acute and delayed nausea and vomiting in patients receiving cytotoxic chemotherapy.
• Radiation‑induced nausea and vomiting: prevents nausea and vomiting associated with therapeutic radiation.
• Post‑operative nausea and vomiting: helps control nausea and vomiting after surgical procedures.

• Ondansetron selectively blocks peripheral and central serotonin (5‑HT3) receptors located in the chemoreceptor trigger zone and gastrointestinal tract. By antagonizing these receptors, it interrupts the signaling cascade that initiates nausea and vomiting, thereby providing anti‑emetic protection during chemotherapy, radiation, and postoperative periods.

Common Side Effects

• Headache: mild to moderate pain often reported during therapy.
• Constipation: reduced bowel movements may occur.
• Dizziness: transient sensation of light‑headedness.

Serious or Rare Side Effects

• QT interval prolongation: may lead to cardiac arrhythmias.
• Severe allergic reaction (anaphylaxis): includes rash, swelling, and breathing difficulty.
• Serotonin syndrome: rare but potentially life‑threatening when combined with other serotonergic agents.

Before initiating therapy, consider the following precautions.

• Assess cardiac risk: evaluate baseline ECG in patients with known QT prolongation.
• Avoid concomitant QT‑prolonging agents: co‑administration may increase arrhythmia risk.
• Use with caution in hepatic impairment: dose adjustment may be required.
• Monitor electrolytes: correct hypokalemia or hypomagnesemia before treatment.
• Pregnancy and lactation: safety not established; weigh benefits against potential risks.
• Store at ambient temperature below 25 °C: keep in the original container, protect from moisture and light.

Ondansetron Stada can interact with several medicines; awareness of the interaction level is essential.

Major Interactions (Avoid)

• Other 5‑HT3 antagonists: additive anti‑emetic effect not recommended.
• QT‑prolonging drugs (e.g., quinidine, haloperidol): increased risk of cardiac arrhythmia.
• Apomorphine: may cause severe hypotension and loss of consciousness.

Moderate Interactions (Monitor Closely)

• Cisplatin and other chemotherapeutics: may enhance nausea control but monitor for additive toxicity.
• CYP3A4 inhibitors (e.g., ritonavir): can raise ondansetron plasma concentrations.
• Serotonergic agents (e.g., SSRIs, triptans): risk of serotonin syndrome requires vigilance.